932-P: MiniMed 780G System Use in a Real-World United States (U.S.) Population Aged 65 Years and Older with Diabetes

Introduction and Objective: Management of dysglycemia in older adults with insulin-requiring diabetes can be challenging and automated insulin delivery is reported to improve glycemic outcomes in this population.1,2 The present study evaluated MiniMedTM 780G system (MM780G) performance in a real-world US population aged ≥65 years. Methods: CareLink™ data (up to December 18, 2024) of consenting US MM780G users (N=8,542, aged ≥65 years) were aggregated and assessed. Sensor glucose (SG) metrics including mean time at SG ranges (time in range [TIR], in tight range [TITR], below range [TBR] and above range [TAR]), the glucose management indicator (GMI) and insulin were evaluated. Users and non-users of recommended optimal settings (ROS: 100mg/dL glucose target with 2 hours active insulin time) were compared. Results: Overall TIR was 78.4%, TITR was 51.4%, TBR70 was 0.9%, TAR180 was 20.7%, TAR250 was 3.6% and GMI was 6.8% (Table). Compared to non-ROS users, the TIR and TITR of ROS users were significantly higher (P<0.001), while TAR and GMI were significantly lower (P<0.001) and TBR was unchanged (<1%). Both groups had the same number of daily user-initiated boluses. Conclusion: A US population of older adults using the MiniMedTM 780G system met international consensus glycemic targets and use of ROS enabled many to achieve an even higher level of glycemic control, without any additional manual boluses. C.A. Chien: Employee; Medtronic. J. Shin: Employee; Medtronic. M. Liu: Employee; Medtronic. Z. Dai: Employee; Metronics. A. Arrieta: Employee; Medtronic. T.L. Cordero: Employee; Medtronic. A.R. Swensen: Employee; Medtronic, Alcon Laboratories, Inc., Karuna Therapeutics. R.A. Vigersky: Employee; Medtronic.